Approval · Notice of Compliance 25022 · 2021
EXTAVIA: Notice of Compliance 25022
Issued January 14, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25022
- Date
- January 14, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXTAVIA | Not yet assigned | — |
Medicinal ingredients
- INTERFERON BETA-1B 0.3 MG per VIAL